Professor Pravin U. Dugel, MD
Pravin Dugel, Clinical Professor at the Roski Eye Institute, University of Southern California, USA, provides his expert insight into key data presented at EURETINA 2019 and discusses the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD.
- Why retinal fluid is important as a marker of disease activity in patients with nAMD. Focus on the rationale for and evidence to support using the retinal fluid as a marker
- How can the burden of nAMD be reduced, and patient adherence and QoL improved? Focus on treatment regimens that improve patient outcomes
- Potential benefits of a smaller-size anti-VEGF therapy on dosing. Focus on how the dosing benefits of smaller-sized anti-VEGF therapies may impact clinical outcomes